Oncology News Central Peer-Spectives
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
Episodes (100)
”We’re Past the Inflection Point,” as ”Massive Change” Hits Breast Cancer Care
Oncology News Central Peer-Spectives
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA”?
Oncology News Central Peer-Spectives
”Very Important” Myeloma Data: ASCO Highlights, Smoldering Challenges, and More
Oncology News Central Peer-Spectives
Durvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”
Oncology News Central Peer-Spectives
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers ”Fantastic” P...
Oncology News Central Peer-Spectives
Should All Breast Cancer Patients Get T-DXd? ”Results of DESTINY-Breast06 Do Sug...
Oncology News Central Peer-Spectives
Oncologist Shortage “Has Gotten to the Crisis Level”
Oncology News Central Peer-Spectives
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
Oncology News Central Peer-Spectives
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
Oncology News Central Peer-Spectives
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
Oncology News Central Peer-Spectives
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”
Oncology News Central Peer-Spectives
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care
Oncology News Central Peer-Spectives
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression
Oncology News Central Peer-Spectives
Controversies, Difficult Questions Arise in NSCLC Amid New Data
Oncology News Central Peer-Spectives
What FDA Approval of Belzutifan Means for Kidney Cancer Care
Oncology News Central Peer-Spectives
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer
Oncology News Central Peer-Spectives
Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 20...
Oncology News Central Peer-Spectives
“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances
Oncology News Central Peer-Spectives
Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Stro...
Oncology News Central Peer-Spectives
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2...
Oncology News Central Peer-Spectives
Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learne...
Oncology News Central Peer-Spectives
First-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy
Oncology News Central Peer-Spectives
What Recent “Outstanding Results” in MCL Mean for Practice
Oncology News Central Peer-Spectives
The Quest to Cure CLL: “Remarkable” Results With New Strategy
Oncology News Central Peer-Spectives
Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Chan...
Oncology News Central Peer-Spectives
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations
Oncology News Central Peer-Spectives
More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists
Oncology News Central Peer-Spectives
Will HER3 Targeting Change Breast Cancer Care?
Oncology News Central Peer-Spectives
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now
Oncology News Central Peer-Spectives
“Don’t Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast...
Oncology News Central Peer-Spectives
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?
Oncology News Central Peer-Spectives
“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Pract...
Oncology News Central Peer-Spectives
“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”
Oncology News Central Peer-Spectives
Pragmatica-Lung Tests a Treatment and a New Approach to Trials
Oncology News Central Peer-Spectives
The Best First Step in Metastatic NSCLC Care
Oncology News Central Peer-Spectives
Neo- and Adjuvant Treatments Are Changing Care in Early NSCLC
Oncology News Central Peer-Spectives
NALIRIFOX Changes Care in Pancreatic Cancer: Here’s How
Oncology News Central Peer-Spectives
Matching Breast Cancer Patients to Therapies: Here’s How
Oncology News Central Peer-Spectives
Myelofibrosis Remains Tough to Treat, But New Drugs Are Paving the Way
Oncology News Central Peer-Spectives
KRAS Inhibition in NSCLC: When, How, and Why?
Oncology News Central Peer-Spectives
Strategies for Navigating a Hematology/Oncology Fellowship
Oncology News Central Peer-Spectives
Taking Aim at MET and KRAS in NSCLC
Oncology News Central Peer-Spectives
Mantle Cell Lymphoma: Optimizing Current Therapies
Oncology News Central Peer-Spectives
COSMIC-313 trial and the Complex Treatment Landscape for Metastatic Renal Cell C...
Oncology News Central Peer-Spectives
Finding Joy in Work: ASCO’s Career Development Resources Help Trainees Choose Th...
Oncology News Central Peer-Spectives
Considering an Oncology Fellowship? Listen to This First
Oncology News Central Peer-Spectives
Kidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients
Oncology News Central Peer-Spectives
How to Choose CLL Treatments in the Frontline Setting
Oncology News Central Peer-Spectives
Rethinking HER2-Targeted Therapy After DESTINY-04
Oncology News Central Peer-Spectives
Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immun...
Oncology News Central Peer-Spectives